New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11 Data supporting mechanism of action for INO-3107 to be presented at 36th International Papillomavirus Conference in Ed ...

PLYMOUTH MEETING, Pa., Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2024 financial results will be released after the market close on November 14, 2024. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general ...

American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy: New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papillomaInternational Society of Vaccines Conference: Full safety and efficacy data from Phase 1/2 clinical study in patients with Recurrent Respiratory Papillomatosis (RRP) indicated that INO-3107 was well tolerated and immunogenic ...

Inovio Pharmaceuticals (INO) shares soared 6.8% in the last trading session to close at $5.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 16.9% loss over the past four weeks. The stock price rally can be attributed to positive investor mindset regarding the potential of Inovio's novel pipeline of DNA medicine candidates being developed for HPV-related diseases, immune-oncology and infectious diseases, across various stages o ...

PLYMOUTH MEETING, Pa., Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO Abstract Title: Reduction in Surgical In ...

PLYMOUTH MEETING, Pa., Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIO Abstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies emplo ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President & Chief Executive Officer Steve Egge - Chief Commercial Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Operato ...

Clinical Trials and Regulatory Updates - INO-3107 BLA submission delayed to mid-2025 due to manufacturing issues with the single-use disposable administration component of the CELLECTRA® device[2][3] - INO-3107 designated as an innovative medicine under the U.K.'s Innovative Licensing and Access Pathway (ILAP) and received Advanced Therapy Medicinal Product (ATMP) Certification from the European Medicines Agency[3] - INO-3112 Phase 3 trial design submitted to European regulatory authorities, with plans to investigate INO-3112 in combination with LOQTORZI for oropharyngeal squamous cell carcinoma (OPSCC)[4] - INO-4201 Phase 2/3 clinical trial protocol for Ebola booster expected to be submitted to the FDA in Q3 2024[5] Financial Performance and Cash Position - Cash, cash equivalents, and short-term investments totaled $110.4 million as of June 30, 2024, compared to $145.3 million as of December 31, 2023[7] - R&D expenses for Q2 2024 were $23.1 million, a slight decrease from $23.7 million in Q2 2023[7] - G&A expenses for Q2 2024 were $10.2 million, down from $13.5 million in Q2 2023[7] - Net loss for Q2 2024 was $32.2 million, or $1.19 per share, compared to a net loss of $35.5 million, or $1.61 per share, in Q2 2023[7] - INOVIO estimates its cash runway to extend into Q3 2025, with an operational net cash burn estimate of approximately $28 million for Q3 2024[9] - Cash and cash equivalents increased to $34,392,404 as of June 30, 2024, compared to $14,310,862 as of December 31, 2023[14] - Short-term investments decreased to $76,029,116 as of June 30, 2024, from $130,982,913 as of December 31, 2023[14] - Total current assets decreased to $117,561,045 as of June 30, 2024, from $153,113,100 as of December 31, 2023[14] - Total liabilities decreased to $37,057,996 as of June 30, 2024, from $53,602,294 as of December 31, 2023[14] - Revenue from collaborative arrangements and other contracts for the six months ended June 30, 2024, was $100,762, compared to $340,914 for the same period in 2023[15] - Research and development expenses for the six months ended June 30, 2024, were $44,001,307, compared to $53,920,481 for the same period in 2023[15] - General and administrative expenses for the six months ended June 30, 2024, were $20,781,337, compared to $27,413,708 for the same period in 2023[15] - Net loss for the six months ended June 30, 2024, was $(62,706,969), compared to $(76,183,850) for the same period in 2023[15] - Basic and diluted net loss per share for the six months ended June 30, 2024, was $(2.48), compared to $(3.50) for the same period in 2023[15] - Weighted average number of common shares used to compute net loss per share for the six months ended June 30, 2024, was 25,244,657, compared to 21,784,343 for the same period in 2023[15] Leadership and Organizational Updates - Steve Egge appointed as Chief Commercial Officer to lead commercial strategy and operations, bringing extensive experience in HPV, immunology, and rare diseases[6]

PLYMOUTH MEETING, Pa., Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments. "We continue to make progress with our lead candidate, INO-3107, which has the potential to significantly improve the lives of patients with R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | |-----------------------------------------------------------------------------------------------------------------------|-------------------------------- ...